--- title: A Guide to Sample Size Re-Estimation in Clinical Trials [Webinar] description: This webinar explores the challenges faced when designing & conducting clinical trials with sample size re-estimation (SSR). We explore SSR methods, their pros, & cons, with real-world examples. image: https://www.statsols.com/hubfs/Guide-to-Sample-Size-Re-estimation-in-Clinical-Trials-sign-up.jpg --- [![nQuery Logo-White](https://www.statsols.com/hs-fs/hubfs/nQuery%20Logo-White.png?width=705&height=175&name=nQuery%20Logo-White.png "nQuery Logo-White")](https://www.statsols.com/) ** ** ![Sample size and power training for use in clinical trials](https://www.statsols.com/hs-fs/hubfs/Master_Images/___PageImages/Software_Training/Sample%20size%20and%20power%20training%20for%20use%20in%20clinical%20trials.jpeg?width=1000&name=Sample%20size%20and%20power%20training%20for%20use%20in%20clinical%20trials.jpeg "Sample size and power training for use in clinical trials") #### Webinar # **Guide to Sample Size** # **  Re-Estimation in Clinical Trials** ### **Approaches for blinded and unblinded sample size re-estimation** #### This webinar has now ended Watch on Demand ** #### About the webinar We explore common challenges faced when designing and conducting clinical trials with sample size re-estimation (SSR). Common SSR methods are explored along with their pros and cons. We also examine some real world examples of these methods, while taking a look at what advantages their use can bring. ** #### In this free webinar, you will learn about: - **Unblinded Sample Size Re-estimation for Means Data** - Cui-Hung-Wang SSR - Chen-DeMets-Lan SSR - **Blinded Sample Size Re-Estimation** - Internal Pilot approach #### More about the webinar Sample Size Re-Estimation (SSR) is a type of adaptive trial design in which the total sample size can be re-estimated at an interim point in the trial. Its use has become increasingly common and important in the clinical trial landscape. Due to the complex nature of these adaptive trials, some unique challenges are faced.  SSR can largely be split into two areas, blinded SSR (BSSR) and unblinded SSR (USSR). These aim to target different aspects of the uncertainty around the initial sample size determination of the trial.  BSSR is very useful in tackling the possible misspecification of any nuisance parameters, for example the variance. Whereas USSR will instead aim to focus on providing an unblinded estimate for the effect size and so aims to address any uncertainty regarding the magnitude of the initial effect size estimate used in the sample size determination.  In this webinar, we will examine both of these areas and discuss some of the popular methods within each area. Utilising some real-world examples to illustrate the challenges and solutions these methods provide. ** #### Duration - 60 minutes **Speaker:** Brian Fox, nQuery Research Statistician, Statsols ### Watch Now All info submitted is secure. View our [privacy policy](https://www.statsols.com/privacy-policy). ** About Our Host **Brian Fox ![Brian Fox - nQuery Researcher - no bg](https://www.statsols.com/hs-fs/hubfs/Staff_Photos/Headshots/Brian%20Fox%20-%20nQuery%20Researcher%20-%20no%20bg.png?width=150&name=Brian%20Fox%20-%20nQuery%20Researcher%20-%20no%20bg.png) #### nQuery Research Statistician **Reducing the risk & cost of clinical trials, for innovative organizations such as:** ![Sanofi-updated-grey](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Sanofi-updated-grey.jpg?width=80&name=Sanofi-updated-grey.jpg "Sanofi-updated-grey") ![worldwide-clinical-trials](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/worldwide-clinical-trials.jpg?width=300&name=worldwide-clinical-trials.jpg "worldwide-clinical-trials") ![Covance-G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Covance-G_Logo.jpg?width=354&name=Covance-G_Logo.jpg "Covance-G_Logo") ![quintiles_logo_2017_grey](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/quintiles_logo_2017_grey.jpg?width=300&name=quintiles_logo_2017_grey.jpg "quintiles_logo_2017_grey") ![FDA_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/FDA_G_Logo.jpg?width=60&name=FDA_G_Logo.jpg "FDA_G_Logo") ![AstellasG_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/AstellasG_Logo.jpg?width=291&name=AstellasG_Logo.jpg "AstellasG_Logo") ![celgene_logo_download](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/celgene_logo_download.jpg?width=91&name=celgene_logo_download.jpg "celgene_logo_download") ![Boehringer_Ingelheim_Logo-png-updated](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Boehringer_Ingelheim_Logo-png-updated.jpg?width=300&name=Boehringer_Ingelheim_Logo-png-updated.jpg "Boehringer_Ingelheim_Logo-png-updated") ![PRA_Health_Sciences](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/PRA_Health_Sciences.jpg?width=68&name=PRA_Health_Sciences.jpg "PRA_Health_Sciences") ![Astrazeneca logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Astrazeneca%20logo.png?width=322&name=Astrazeneca%20logo.png "Astrazeneca logo") ![Amgen_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Amgen_G_Logo.jpg?width=350&name=Amgen_G_Logo.jpg "Amgen_G_Logo") ![Novartis_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Novartis_G_Logo.jpg?width=508&name=Novartis_G_Logo.jpg "Novartis_G_Logo") ![abbvie-logo-updated_tmp15240](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/abbvie-logo-updated_tmp15240.jpg?width=365&name=abbvie-logo-updated_tmp15240.jpg "abbvie-logo-updated_tmp15240") ![Merck_GLogo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Merck_GLogo.jpg?width=310&name=Merck_GLogo.jpg "Merck_GLogo") ![Biogen-updated-logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Biogen-updated-logo.jpg?width=258&name=Biogen-updated-logo.jpg "Biogen-updated-logo") ![Ipsen-logo-only](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Ipsen-logo-only.jpg?width=300&name=Ipsen-logo-only.jpg "Ipsen-logo-only") ![Eli_Lilly_and_Company-G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Eli_Lilly_and_Company-G_Logo.jpg?width=120&name=Eli_Lilly_and_Company-G_Logo.jpg "Eli_Lilly_and_Company-G_Logo") ###### Is there someone in your network that would be interested in our webinar? Share this page by clicking below. [![Share on linkedin](https://7528302.fs1.hubspotusercontent-na1.net/hub/7528302/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/linkedin-color.png?width=24&name=linkedin-color.png) ](http://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fguide-to-sample-size-reestimation-in-clinical-trials%3Futm_medium%3Dsocial%26utm_source%3Dlinkedin) [![Share on twitter](https://7528304.fs1.hubspotusercontent-na1.net/hub/7528304/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/twitter-color.png?width=24&name=twitter-color.png) ](https://twitter.com/intent/tweet?original_referer=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fguide-to-sample-size-reestimation-in-clinical-trials%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&url=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fguide-to-sample-size-reestimation-in-clinical-trials%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&source=tweetbutton&text=) [![Share on email](https://7528311.fs1.hubspotusercontent-na1.net/hub/7528311/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/email-color.png?width=24&name=email-color.png) ](mailto:?subject=Check%20out%20https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fguide-to-sample-size-reestimation-in-clinical-trials%3Futm_medium%3Dsocial%26utm_source%3Demail%20&body=Check%20out%20https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fguide-to-sample-size-reestimation-in-clinical-trials%3Futm_medium%3Dsocial%26utm_source%3Demail)